APA (7th ed.) Citation

Negrier, C., Young, G., Abdul Karim, F., Collins, P. W., Hanabusa, H., Colberg, T., . . . Walsh, C. E. (2016). Recombinant long-acting glyco PEGylated factor IX (nonacog beta pegol) in haemophilia B: Assessment of target joints in multinational phase 3 clinical trials. Haemophilia, 22(4), 507. https://doi.org/10.1111/hae.12902

Chicago Style (17th ed.) Citation

Negrier, C., G. Young, F. Abdul Karim, P. W. Collins, H. Hanabusa, T. Colberg, B. Goldman, and C. E. Walsh. "Recombinant Long-acting Glyco PEGylated Factor IX (nonacog Beta Pegol) in Haemophilia B: Assessment of Target Joints in Multinational Phase 3 Clinical Trials." Haemophilia 22, no. 4 (2016): 507. https://doi.org/10.1111/hae.12902.

MLA (9th ed.) Citation

Negrier, C., et al. "Recombinant Long-acting Glyco PEGylated Factor IX (nonacog Beta Pegol) in Haemophilia B: Assessment of Target Joints in Multinational Phase 3 Clinical Trials." Haemophilia, vol. 22, no. 4, 2016, p. 507, https://doi.org/10.1111/hae.12902.